# MARGetuximab Or Trastuzumab (MARGOT)

Source: https://onco.cc/trials/nct04425018/  
OnCo record `nct04425018` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Paclitaxel / nab-paclitaxel, Pertuzumab, Margetuximab, Trastuzumab and Trastuzumab biosimilars in Breast cancer and HER2-positive breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.

## Summary

MARGetuximab Or Trastuzumab (MARGOT) is a phase 2 interventional study registered as NCT04425018 by Dana-Farber Cancer Institute, with 174 participants planned, started 2020-07-13 and due to reach its primary completion in 2024-10-24. Interventions recorded: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab. Conditions recorded: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer.

Linked to the drug Margetuximab because the registry names it among its interventions and Breast cancer and HER2-positive breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04425018
- Phase: 2
- Setting: MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 174

## Sources

- ClinicalTrials.gov NCT04425018: https://clinicaltrials.gov/study/NCT04425018

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Margetuximab](https://onco.cc/drugs/margetuximab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab biosimilars](https://onco.cc/drugs/trastuzumab-biosimilars/)

---
JSON: https://onco.cc/api/v1/entities/nct04425018.json